These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31176538)

  • 1. A descriptive analysis of transgender participants in phase 1-2a trials of the HIV Vaccine Trials Network (HVTN) in the United States and Peru.
    Andrasik M; Grove D; Broder G; Scott H; Allen M; Karuna S
    Vaccine; 2019 Jun; 37(29):3911-3917. PubMed ID: 31176538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engaging Transgender People in NIH-Funded HIV/AIDS Clinical Trials Research.
    Siskind RL; Andrasik M; Karuna ST; Broder GB; Collins C; Liu A; Lucas JP; Harper GW; Renzullo PO
    J Acquir Immune Defic Syndr; 2016 Aug; 72 Suppl 3(Suppl 3):S243-7. PubMed ID: 27429190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Demographic Analysis of Racial/Ethnic Minority Enrollment Into HVTN Preventive Early Phase HIV Vaccine Clinical Trials Conducted in the United States, 2002-2016.
    Huamani KF; Metch B; Broder G; Andrasik M
    Public Health Rep; 2019; 134(1):72-80. PubMed ID: 30517057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody.
    Edupuganti S; Mgodi N; Karuna ST; Andrew P; Rudnicki E; Kochar N; deCamp A; De La Grecca R; Anderson M; Karg C; Tindale I; Greene E; Broder GB; Lucas J; Hural J; Gallardo-Cartagena JA; Gonzales P; Frank I; Sobieszczyk M; Gomez Lorenzo MM; Burns D; Anderson PL; Miner MD; Ledgerwood J; Mascola JR; Gilbert PB; Cohen MS; Corey L;
    J Acquir Immune Defic Syndr; 2021 May; 87(1):671-679. PubMed ID: 33587505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.
    Thiam-Diouf A; Metch B; Sharpe C; Mulugeta R; Andrasik MP
    Vaccine; 2018 Feb; 36(9):1235-1242. PubMed ID: 29395528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa.
    Hanass-Hancock J; Carpenter B; Reddy T; Nzuza A; Gaffoor Z; Goga A; Andrasik M
    Trials; 2021 Dec; 22(1):897. PubMed ID: 34895272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Representation of Latinos and Blacks in screening for and enrollment into preventive HIV vaccine trials in New York City.
    Ellman TM; Hawkins K; Benitez J; Negron R; Chang S; Palmer S; Robertson V; Chiasson MA; Sobieszczyk ME
    Vaccine; 2015 Nov; 33(48):6809-15. PubMed ID: 26458799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Individual and Area Level Factors Between HIV-Infected Cisgender and Transgender Individuals in Florida (2006-2014).
    Fennie KP; Trepka MJ; Maddox LM; Lutfi K; Lieb S
    AIDS Behav; 2016 Oct; 20(10):2186-2191. PubMed ID: 26885811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring barriers and facilitators to participation of male-to-female transgender persons in preventive HIV vaccine clinical trials.
    Andrasik MP; Yoon R; Mooney J; Broder G; Bolton M; Votto T; Davis-Vogel A; ;
    Prev Sci; 2014 Jun; 15(3):268-76. PubMed ID: 23446435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Sexual Violence Across the Lifespan on HIV Risk Behaviors Among Transgender Women and Cisgender People Living With HIV.
    Smith LR; Yore J; Triplett DP; Urada L; Nemoto T; Raj A;
    J Acquir Immune Defic Syndr; 2017 Aug; 75(4):408-416. PubMed ID: 28653970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Cohort Methods for HIV Research and Epidemiology (ENCORE): Protocol for a Nationwide Hybrid Cohort for Transgender Women in the United States.
    Wirtz AL; Poteat T; Borquez A; Linton S; Stevenson M; Case J; Brown C; Lint A; Miller M; Radix A; Althoff KN; Schneider JS; Haw JS; Wawrzyniak AJ; Rodriguez A; Cooney E; Humes E; Pontes C; Seopaul S; White C; Beyrer C; Reisner SL;
    JMIR Res Protoc; 2024 Aug; 13():e59846. PubMed ID: 39190916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV prevalence among transmasculine individuals at a New York City Community Health Centre: a cross-sectional study.
    Radix AE; Larson EL; Harris AB; Chiasson MA
    J Int AIDS Soc; 2022 Oct; 25 Suppl 5(Suppl 5):e25981. PubMed ID: 36225145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Social Media Use and HIV-Related Risk Behaviors in Young Black and Latino Gay and Bi Men and Transgender Individuals in New York City: Implications for Online Interventions.
    Patel VV; Masyukova M; Sutton D; Horvath KJ
    J Urban Health; 2016 Apr; 93(2):388-99. PubMed ID: 26936854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A life course health development model of HIV vulnerabilities and resiliencies in young transgender women in Peru.
    Reisner SL; Aguayo-Romero RA; Perez-Brumer A; Salazar X; Nunez-Curto A; Orozco-Poore C; Silva-Santisteban A
    Glob Health Res Policy; 2023 Aug; 8(1):32. PubMed ID: 37605284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Social Impacts Among Participants in HIV Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials.
    Andrasik MP; Sesay FA; Isaacs A; Oseso L; Allen M
    J Acquir Immune Defic Syndr; 2020 Aug; 84(5):488-496. PubMed ID: 32692107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-related outcome disparities between transgender women living with HIV and cisgender people living with HIV served by the Health Resources and Services Administration's Ryan White HIV/AIDS Program: A retrospective study.
    Klein PW; Psihopaidas D; Xavier J; Cohen SM
    PLoS Med; 2020 May; 17(5):e1003125. PubMed ID: 32463815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV incidence, risk factors, and motivation for biomedical intervention among gay, bisexual men, and transgender persons in Northern Thailand.
    Chariyalertsak S; Kosachunhanan N; Saokhieo P; Songsupa R; Wongthanee A; Chariyalertsak C; Visarutratana S; Beyrer C
    PLoS One; 2011; 6(9):e24295. PubMed ID: 21931673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa.
    Malahleha M; Laher F; Dilraj A; Smith P; Gray GE; Grove D; Odhiambo JA; Andrasik MP; Grunenberg NA; Moodie Z; Huang Y; Borate BR; Gillespie KM; Allen M; Atujuna M; Singh N; Kalonji D; Meintjes G; Kotze P; Bekker LG; Janes H
    AIDS Behav; 2023 Sep; 27(9):3027-3037. PubMed ID: 36929319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Risk Factors of Nonmedical Prescription Opioid Use Among Transgender Girls and Young Women.
    Restar AJ; Jin H; Ogunbajo A; Goedel WC; Millett G; Sherwood J; Kuhns L; Reisner SL; Garofalo R; Mimiaga MJ
    JAMA Netw Open; 2020 Mar; 3(3):e201015. PubMed ID: 32176305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.
    Buchbinder SP; Glidden DV; Liu AY; McMahan V; Guanira JV; Mayer KH; Goicochea P; Grant RM
    Lancet Infect Dis; 2014 Jun; 14(6):468-75. PubMed ID: 24613084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.